Luminally active therapies: Pancreatic enzymes, bile acids, bile acid binders, antimicrobials, probiotics, and prebiotics in short bowel syndrome

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Maldigestion and malabsorption are fundamental problems in the patient afflicted by short bowel syndrome (SBS), and several factors may contribute, including pancreatic insufficiency, depletion of the bile salt pool, and small intestinal bacterial overgrowth (SIBO); all are potential targets for therapeutic intervention. Quite apart from symptoms that may result from malabsorption, changes in luminal contents may contribute to symptomatology in other ways in this clinical context. These include spillage of unabsorbed bile acids into the colon leading to cholereic diarrhea and qualitative and quantitative changes in the microbiome of the small intestine and colon such as are now being revealed by high-throughput sequencing and metabolomics studies. This chapter will review the current status of our understanding of these issues and will attempt to provide guidance for therapy.

Original languageEnglish (US)
Title of host publicationShort Bowel Syndrome
Subtitle of host publicationPractical Approach to Management
PublisherCRC Press
Pages227-240
Number of pages14
ISBN (Electronic)9781498720809
ISBN (Print)9781498720786
DOIs
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Luminally active therapies: Pancreatic enzymes, bile acids, bile acid binders, antimicrobials, probiotics, and prebiotics in short bowel syndrome'. Together they form a unique fingerprint.

Cite this